Safety and efficacy of dual immune checkpoint inhibition for melanoma brain metastases and its comparison to ICI monotherapy: A systematic review and meta-analysis.
Alireza Shariati, Ehsan Mehrtabar, Taher Fanihagh et al.
✦ AI-curated · Sources linked
In 30 seconds
This PRISMA-based systematic review and meta-analysis pooled prospective and retrospective studies of adults with cutaneous or mucosal melanoma brain metastases treated with dual immune checkpoint inhibition (ICI), and compared outcomes with ICI monotherapy where data were available. Across 24 studies involving 3518 patients, pooled intracranial objective response was 42.5%, rising to 48% among first-line dual ICI recipients. Comparative analyses favored dual ICI for overall survival at 6 months, 12 months, and 2 years, but not significantly at 3 years. Benefit was more favorable in asymptomatic than symptomatic patients, alongside substantial treatment-related toxicity.
Key findings
- Pooled intracranial objective response was 42.5% overall and 48% among first-line dual ICI recipients.
- Intracranial progression-free survival was 51.9% at 6 months, 44.1% at 12 months, 40.5% at 2 years, and 38.8% at 3 years.
- Three-year overall survival was 52.3% in asymptomatic patients versus 31.5% in symptomatic patients.
- All-grade treatment-related adverse events occurred in 78% and grade 3 or higher events in 48.2%; dual ICI was associated with more toxicity than monotherapy.
Why it matters
The pooled findings suggest dual ICI can achieve intracranial responses and sustained disease control in melanoma brain metastases, with comparative survival advantages over monotherapy at earlier time points. The less favorable outcomes in symptomatic disease underscore an important unmet need. Because serious treatment-related toxicity was common and higher with dual therapy, the potential benefit must be considered alongside the need for monitoring and management of immune-related complications.
What to keep in mind
The evidence combined prospective and retrospective studies and was heterogeneous. The authors note that limited data and substantial heterogeneity leave the 3-year survival advantage uncertain.